Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.

Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J.

PLoS Pathog. 2012;8(6):e1002739. doi: 10.1371/journal.ppat.1002739.

2.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

3.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

4.

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M; NISC Comparative Sequencing Program., Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR.

Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532.

5.

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC.

Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227.

6.

An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF.

J Virol. 2011 Jul;85(14):7029-36. doi: 10.1128/JVI.00171-11.

7.

Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure.

Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, Stratov I.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7505-10. doi: 10.1073/pnas.1016048108.

8.

Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection.

Isitman G, Chung AW, Navis M, Kent SJ, Stratov I.

Virology. 2011 Mar 30;412(1):110-6. doi: 10.1016/j.virol.2010.12.044.

9.

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.

Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G.

J Immunol Methods. 2011 Mar 7;366(1-2):8-19. doi: 10.1016/j.jim.2010.12.016. Erratum in: J Immunol Methods. 2012 Feb 28;376(1-2):156.

10.

The humoral response to HIV-1: new insights, renewed focus.

Alter G, Moody MA.

J Infect Dis. 2010 Oct 15;202 Suppl 2:S315-22. doi: 10.1086/655654. Review.

11.

Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.

Alpert MD, Rahmberg AR, Neidermyer W, Ng SK, Carville A, Camp JV, Wilson RL, Piatak M Jr, Mansfield KG, Li W, Miller CJ, Lifson JD, Kozlowski PA, Evans DT.

J Virol. 2010 Oct;84(20):10748-64. doi: 10.1128/JVI.00945-10.

12.

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, Hidajat R, Demberg T, Robert-Guroff M.

J Virol. 2010 Jul;84(14):7161-73. doi: 10.1128/JVI.00410-10.

13.

Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1.

Salisch NC, Kaufmann DE, Awad AS, Reeves RK, Tighe DP, Li Y, Piatak M Jr, Lifson JD, Evans DT, Pereyra F, Freeman GJ, Johnson RP.

J Immunol. 2010 Jan 1;184(1):476-87. doi: 10.4049/jimmunol.0902781.

14.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators..

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492.

15.

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR.

Nat Med. 2009 Aug;15(8):951-4. doi: 10.1038/nm.1974.

16.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433.

17.

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Jia B, Ng SK, DeGottardi MQ, Piatak M, Yuste E, Carville A, Mansfield KG, Li W, Richardson BA, Lifson JD, Evans DT.

PLoS Pathog. 2009 Jan;5(1):e1000272. doi: 10.1371/journal.ppat.1000272.

18.

Rapid degranulation of NK cells following activation by HIV-specific antibodies.

Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I.

J Immunol. 2009 Jan 15;182(2):1202-10.

19.

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M.

J Virol. 2009 Jan;83(2):791-801. doi: 10.1128/JVI.01672-08.

20.

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.

Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, Kaizu M, Soma T, León EJ, MacNair C, Leaman DP, Zwick MB, Gostick E, Musani SK, Price DA, Friedrich TC, Rakasz EG, Wilson NA, McDermott AB, Boyle R, Allison DB, Burton DR, Koff WC, Watkins DI.

J Exp Med. 2008 Oct 27;205(11):2537-50. doi: 10.1084/jem.20081524.

Supplemental Content

Support Center